Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 6, 2012, Pages 2242-2246

  Jiao, Guan Sheng ^a   Kim, Seongjin ^a   Moayeri, Mahtab ^b   Crown, Devorah ^b   Thai, April ^a   Cregar Hernandez, Lynne ^a   McKasson, Linda ^a   Sankaran, Banumathi ^c   Lehrer, Axel ^a   Wong, Teri ^a   Johns, Lisa ^a   Margosiak, Stephen A ^a   Leppla, Stephen H ^b   Johnson, Alan T ^a  

^a PanThera Biopharma LLC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Anthrax; In vitro ADME; Inhibitor; Lethal factor; X ray crystallography

Indexed keywords

ANTHRAX LETHAL FACTOR; ANTHRAX LETHAL FACTOR INHIBITOR; ANTIDOTE; METALLOPROTEINASE; PHENOXYACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG STRUCTURE; INTOXICATION; LETHAL GENE; MICROSOME; MOLECULAR INTERACTION; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; RAT; X RAY CRYSTALLOGRAPHY;

ACETIC ACIDS; ANIMALS; ANTHRAX; ANTIDOTES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 CYP2D6; MICROSOMES, LIVER; MODELS, MOLECULAR; RABBITS; RATS;

RATTUS;

EID: 84862818898     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.01.095     Document Type: Article

References (21)

1. J.-N. Tournier, S.R. Paccani, A. Quesnel-Hellmann, and C.T. Baldari Mol. Aspects Med. 30 2009 456
2. N.S. Duesbury, C.P. Webb, S.H. Leppla, V.M. Gordon, T.D. Copeland, N.G. Ahn, M.K. Oskarsson, K. Fukasawa, K.D. Paull, and G.F. Vande Woude Science 280 1998 734
3. G. Vitale, L. Bernardi, G. Napolitani, M. Mock, and C. Montecucco Biochem. J. 352 2000 739
4. S.H. Leppla Proc. Natl. Acad. Sci. U.S.A. 79 1982 3162
5. W.-J. Tang, and Q. Guo Mol. Aspects Med. 30 2009 423
6. R.J. Collier, and J.A. Young Annu. Rev. Cell Dev. Bio. 19 2003 45
7. M. Moayeri, and S.H. Leppla Mol. Aspects Med. 30 2009 439
8. J.-E.C. Holty, D.M. Bravata, H. Liu, R.A. Olshen, K.M. McDonald, and D.K. Owens Ann. Intern. Med. 144 2006 270
9. J.A. Jernigan, D.S. Stephens, D.A. Ashford, C. Omenaca, M.S. Topiel, and M. Galbraith Emerg. Infect Dis. 7 2001 933
10. S. Kim, G.-S. Jiao, M. Moayeri, D. Crown, L. Cregar-Hernandez, L. McKasson, S.S. Margosiak, S.H. Leppla, and A.T. Johnson Bioorg. Med. Chem. Lett. 21 2011 2030
11. W.L. Shoop, Y. Xiong, J. Wiltsie, and A. Woods Proc. Natl. Acad. Sci. U.S.A. 102 2005 7958
12. M.A. Holmes, and B.W. Matthews Biochemistry 20 1981 6912
13. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng Curr. Med. Chem. 8 2001 425
14. This image was made with VMD which was developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign. http://www.ks.uiuc.edu/Research/vmd/ .
15. D.A. Smith, H. van de Waterbeemd, and D.K. Walker R. Mannhold, H. Kubinyi, H. Timmerman, Methods and Principles in medicinal Chemistry Vol. 13 2001 Wiley-VCH Verlag GmbH Weinheim 78 80
16. D.A. Evans, M.D. Ennis, and D.J. Mathre J. Am. Chem. Soc. 104 1982 1737
17. C. Kaiser, and J. Weinstock Org. Synth. 51 1971 48
18. F. Wohnsland, and B. Faller J. Med. Chem. 44 2001 923
19. Gupta, P.K.; Moayeri, M.; Crown, D.; Fattah, R.J.; Leppla, S.H., PLoS One 2008, 3, e3130. Note: this assay was not designed to model inhalation anthrax in humans but to demonstrate that a small molecule LFI can prevent death due to anthrax lethal factor in an in vivo model. The protocol used provides for a reproducible assay with the resolution necessary to rank order the in vivo efficacy of LFIs in an animal model where death results specifically from the action of anthrax LF.
20. F. Lombardo, M.Y. Shalaeva, K.A. Tupper, and F. Gao J. Med. Chem. 44 2001 2490
21. P.L. Goossens Mol. Aspects Med. 30 2009 467